Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 9/20 | 0.52 |
| ▸ | BACE1 | P56817 | 9/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | FPR1 | P21462 | 4/20 | 0.41 |
| ▸ | FPR2 | P25090 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20255738 | 0.98 | CTSD (0.50) | CTSDBACE1ALDH1A1FOLH1CTSB | |
| SCHEMBL21012039 | 0.98 | CTSD (0.50) | CTSDBACE1ALDH1A1FOLH1CTSB | |
| SCHEMBL17210507 | 0.95 | CTSD (0.50) | CTSDBACE1ALDH1A1FOLH1CTSB | |
| SCHEMBL17951617 | 0.93 | CTSD (0.49) | CTSDBACE1ALDH1A1FOLH1CTSB | |
| SCHEMBL17951689 | 0.90 | ALDH1A1 (0.58) | CTSDBACE1ALDH1A1FOLH1 | |
| SCHEMBL16557150 | 0.88 | ALDH1A1 (0.65) | CTSDBACE1ALDH1A1FOLH1 | |
| SCHEMBL21049238 | 0.88 | ALDH1A1 (0.60) | CTSDBACE1ALDH1A1FOLH1CTSB | |
| SCHEMBL21049237 | 0.88 | ALDH1A1 (0.60) | CTSDBACE1ALDH1A1FOLH1CTSB | |
| SCHEMBL17536609 | 0.88 | ALDH1A1 (0.60) | CTSDBACE1ALDH1A1FOLH1CTSB | |
| SCHEMBL17536608 | 0.88 | ALDH1A1 (0.60) | CTSDBACE1ALDH1A1FOLH1CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160213742-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2016-07-28 | — | — | US | disclosed |
| WO-2015164289-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2015-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160213742-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS | FPR1, FPR3, FPR2 | CTSD 1086/4885BACE1 432/4885ALDH1A1 3893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.